Introduction
More recent estimates of HCV cases in Scotland, and reference to its current global disease burden would be more useful here. The authors hypothesise that the treatment outcomes of the second and third (fortnightly dispensed) treatment modalities won't be inferior to DOT quite late in the article (page 10,line 26). Suggest bringing this forward to the Introduction section, meanwhile qualifying and referencing the assertion that DOT is 'costly and draconian' (page 6, line: 26-7). DOT's advantages of being convenient, and not as costly when administered daily in tandem with opioid replacement therapies, might also be mentioned here; likewise, DOT's enabling of early identification and management of any treatment side effects and or drug interactions (a common reason for poor adherence). The authors might avoid unreferenced assertions in this early section such as "[fortnightly provision of medication] passes some of the responsibility for adherence onto the individual patients...embraces a realistic medicine approach, putting the patient at the centre of care, empowering the patients to take control of their own health" (page 6, lines:28-32). There might also be acknowledgment here that homeless people may have particular difficulty storing their own medications; may have limited privacy in public housing situations potentially compromising their confidentiality. While provided free-of charge by the pharmaceutical company for this trial, the otherwise very significant cost associated with the loss or theft of DAAs in non-trial, real life situations probably also warrants mention here. Further information could be provided here re the success of the respective treatment modalities in enhancing adherence among PWID more generally, the HIV treatment literature providing relevant evidence for this. The statement that "the medical profession's belief that PWID will demonstrate poor adherence to treatment ...due to illicit drug use or alcohol use has hindered treatment opportunities" (page 6, line: 56-8) relies heavily on a single reference. The barriers to health care encountered by vulnerable populations could be further expanded here, emphasising how these will need to be overcome in order to achieve TasP of HCV. Given this TasP focus, also connected to its stated objective: 'To assess re-infection rates in active PWID treated with oral DAA regimes' (page 6, line: 55), reference to the evidence base for its effectiveness in HIV prevention is also warranted in this section. The IEPS trial recruitment site should be more fully described here, including whether HCV treatment is being administered alongside treatment for opioid or other drug dependence in this setting. The usual range of services should be listed along with specific mention of what, if anything, has been added/changed to integrate this trial. While noting that the study is already underway in the final paragraph in this section, the actual start date would be better stated here (vs in the 'Study set up' subsection in the Methods as now).
Methods and Analysis
Objectives Suggest numbering the objectives. The second objective does not read well ("...similar to RCT results -which? ...and therefore "cost effective" -maybe removing "cost" since costs aren't being systematically measured and compared to other treatment modalities in this study.
Eligibility criteria
Review the ordering, grouping those pertaining to abnormal liver function together; avoid same criteria appearing in both lists e.g. ability to consent as an inclusion criteria, and inability to consent as an exclusion criterion. The 'male or female' criterion implies the exclusion of transgender persons. If so, 'transgender' should be an exclusion criterion (with brief explanation) instead. If no genders are excluded then gender does not need to be among the inclusion criteria.
Visit schedule Separate tables per HCV genotype probably not needed here, text explaining the difference sufficing.
Fortnightly treatment regimen with psychological intervention Towards the end of this subsection it states: "A urine sample is also collected among individuals whilst they are on treatment ... [which] may be analysed at the end of the study to detect illicit drugs/metabolites that may have reduced DAA treatment effectiveness". This presumably enables the fifth study objective: "To determine the types of illicit drugs taken by trial participants who do not achieve SVR and assess any interaction with the DAAs". But it is not clear exactly when this single test will occur, and what determines this. While acknowledging the cost implications, it would seem a pity not be undertaking baseline and fortnightly testing thereafter among all participants, thereby enabling this important study objective to be systematically assessed. The timing of this drug testing should be described more explicitly here, also noting the need for it to be accompanied by assurances that these results would be blinded to treating clinicians, and not affect participants' access to other treatments (particularly for drug dependence), and their continued participation in the study. The study's blood and urine testing schedule could warrant its own subsection, or this testing info reported here should be moved to the earlier 'visit schedule' subsection (page 8) since it pertains to all three study arms and not just the 3rd treatment modality here.
Sample size calculation Anticipating only nine (7%) drop outs across the study period seems optimistic! Further information/reference/s needed to support authors' assumption that "the non-inferiority limit of 14% ... would be likely to maintain cost effectiveness".
Safety reporting
Probably unnecessary to list the various categories not being regarded as adverse events here.
Analysis plan
The three sub-cohorts should be compared demographically etc to assess the randomisation. This sub-section should also include plans for assessing the other study objectives including HCV re-infection rates, resistance profiles and drug interactions.
More minor points The study compares three different ways of administering/dispensing DAAs, and not the actual treatment regimens (as per the article's title), which are the same across the three arms. While also referring more correctly to the different 'treatment dispensing regimens' in the text, to avoid any confusion I suggest referring to the three study arms as [treatment] 'modalities' instead of '[dispensing] regimens' throughout. Suggest more common 'needle syringe programs' term instead of 'injecting equipment provision sites' for this international journal. 'Hepatitis' [C virus] does not need upper case; DAA 'treatment' and 'therapy' used interchangeably -suggest 'treatment' throughout; re: DAAs, suggest using 'medication' instead of 'drug' in a paper which also refers to illicit 'drug' use. Abbreviations not always preceded by the term in full (esp in Abstract), or full term used despite previously being abbreviated; some assumed abbreviations (e.g. NHS) should be in full.
Text waxes between present and future tense -should be consistent, and probably present tense since the study is currently in train. Some long-winded paragraphs and sentences (e.g. page 5, line 47 -51; page 6, para 1,2; page 8, lines:22-27), which could be shortened or fragmented, with information expressed more succinctly.
REVIEWER
Peng Huang Nanjing Medical University REVIEW RETURNED 12-Apr-2019
GENERAL COMMENTS
The study design of Inglis S.K. et al. is innovative and rigorous in design. However, there are still some issues which needed to consider: 1. Does this study exclude patients with other liver diseases or severely consumptive or critical diseases? 2.
How to treat patients who have received antiviral treatment in the past? 3.
There are many indicators of virology. Why do authors only consider SVR12? 4.
Why not collect blood samples during follow-up to understand the change trend of patient's serum viral load? 5.
The subjects should be randomly grouped, and the method of random grouping is not given in the scheme. 6.
Please explain how to improve the compliance of the subjects during the follow-up process. Please leave your comments for the authors below This is a study protocol for what the authors describe as a 'pragmatic parallel three-armed randomised controlled clinical trial (RCT) of hepatitis C (HCV) treatment' being conducted among people who inject drugs (PWID) in Tayside, Scotland. This RCT will enable the comparison of the treatment efficacy of standard regimens of directly acting anti-viral medications (DAAs) for HCV genotypes 1 and 3 delivered in three different ways. These include directly observed therapy (DOT) at an injecting equipment provision site (IEPS); and fortnightly collection of daily oral DAAs from the same site, with and without the administration of a 'psychological intervention designed to improve adherence' prior to commencing treatment. Its findings will contribute to our understanding in this still challenging sphere of public health. Abstract Intro: suggest tempering the 3rd sentence (Page 3, lines: 10-12) to reflect that modelling of [HCV] treatment as prevention (TasP) shows there may also be public health benefits of HCV treatment if its coverage is extended to include those currently engaged in risky injecting behaviours -but that this is yet to be demonstrated in a real-life setting. Text changed in this section Introduction More recent estimates of HCV cases in Scotland, and reference to its current global disease burden would be more useful here. The figures reported are the most up-to-date currently available publicly for Scotland. Text has been added to outline the global burden of hepatitis C.
VERSION 1 -AUTHOR RESPONSE
The authors hypothesise that the treatment outcomes of the second and third (fortnightly dispensed) treatment modalities won't be inferior to DOT quite late in the article (page 10,line 26). Suggest bringing this forward to the Introduction section, meanwhile qualifying and referencing the assertion that DOT is 'costly and draconian' (page 6, line: 26-7). The description of the 3 treatment regimens in the introduction has been amended to take account of the reviewer's comments.
DOT's advantages of being convenient, and not as costly when administered daily in tandem with opioid replacement therapies, might also be mentioned here; likewise, DOT's enabling of early identification and management of any treatment side effects and or drug interactions (a common reason for poor adherence). Whilst we have successfully used DOT regimens to treat people attending community pharmacies for opioid replacement therapies, the PWID population targeted by this current study actively inject drugs and are mostly not on ORT. Therefore they do not attend the IEPS daily. We have taken account of the reviewer's comments and removed reference to potential reasons for why one regimen may lead to better adherence than the others. Since this is a protocol paper we do not yet know which pathway will be best. We will discuss possible reasons for any pathway performing best in the final, results paper.
The authors might avoid unreferenced assertions in this early section such as "[fortnightly provision of medication] passes some of the responsibility for adherence onto the individual patients...embraces a realistic medicine approach, putting the patient at the centre of care, empowering the patients to take control of their own health" (page 6, lines:28-32). There might also be acknowledgment here that homeless people may have particular difficulty storing their own medications; may have limited privacy in public housing situations potentially compromising their confidentiality. Please see above comment. We welcome the reviewer's comments and as a result have decided to remove postulation about the potential merits of the different pathways and will keep these for discussion in the results paper. While provided free-of charge by the pharmaceutical company for this trial, the otherwise very significant cost associated with the loss or theft of DAAs in non-trial, real life situations probably also warrants mention here. We agree with the reviewer that there is potential for drug theft/loss. However, we have currently recruited over 80 people to this trial and have had no incidences of drug theft and minimal loss. We feel that a discussion of these points will be most appropriate once we have the data at the end of the trial in the results paper.
Further information could be provided here re the success of the respective treatment modalities in enhancing adherence among PWID more generally, the HIV treatment literature providing relevant evidence for this.
Text added line 114+
The statement that "the medical profession's belief that PWID will demonstrate poor adherence to treatment ...due to illicit drug use or alcohol use has hindered treatment opportunities" (page 6, line: 56-8) relies heavily on a single reference. The barriers to health care encountered by vulnerable populations could be further expanded here, emphasising how these will need to be overcome in order to achieve TasP of HCV. Text and refs added from line 82 onwards.
Given this TasP focus, also connected to its stated objective: 'To assess re-infection rates in active PWID treated with oral DAA regimes' (page 6, line: 55), reference to the evidence base for its effectiveness in HIV prevention is also warranted in this section.
Text added (line 67)
The IEPS trial recruitment site should be more fully described here, including whether HCV treatment is being administered alongside treatment for opioid or other drug dependence in this setting. The usual range of services should be listed along with specific mention of what, if anything, has been added/changed to integrate this trial. Text added.
While noting that the study is already underway in the final paragraph in this section, the actual start date would be better stated here (vs in the 'Study set up' subsection in the Methods as now). Text added.
Methods and Analysis
Objectives Suggest numbering the objectives. The second objective does not read well ("...similar to RCT results -which? ...and therefore "cost effective" -maybe removing "cost" since costs aren't being systematically measured and compared to other treatment modalities in this study. In response to this comment and those of the editor, we have replaced the objective and outcome measure text with a table which more clearly sets out the objectives of the study.
Eligibility criteria Review the ordering, grouping those pertaining to abnormal liver function together; avoid same criteria appearing in both lists e.g. ability to consent as an inclusion criteria, and inability to consent as an exclusion criterion. The 'male or female' criterion implies the exclusion of transgender persons. If so, 'transgender' should be an exclusion criterion (with brief explanation) instead. If no genders are excluded then gender does not need to be among the inclusion criteria.
Text altered
Visit schedule Separate tables per HCV genotype probably not needed here, text explaining the difference sufficing. Tables amalgamated into one.
Fortnightly treatment regimen with psychological intervention Towards the end of this subsection it states: "A urine sample is also collected among individuals whilst they are on treatment ... [which] may be analysed at the end of the study to detect illicit drugs/metabolites that may have reduced DAA treatment effectiveness". This presumably enables the fifth study objective: "To determine the types of illicit drugs taken by trial participants who do not achieve SVR and assess any interaction with the DAAs". But it is not clear exactly when this single test will occur, and what determines this. The urine sample is taken at any time during treatment -text added.
While acknowledging the cost implications, it would seem a pity not be undertaking baseline and fortnightly testing thereafter among all participants, thereby enabling this important study objective to be systematically assessed. The timing of this drug testing should be described more explicitly here, also noting the need for it to be accompanied by assurances that these results would be blinded to treating clinicians, and not affect participants' access to other treatments (particularly for drug dependence), and their continued participation in the study. Since the urine testing confirms that the participant is taking illegal drugs we were concerned that requirement for regular urine testing may discourage people from taking part in the study. For this reason only one test is taken, during the treatment period. The urine and blood samples are anonymised for storage -text added to the manuscript to describe this. The study's blood and urine testing schedule could warrant its own subsection, or this testing info reported here should be moved to the earlier 'visit schedule' subsection (page 8) since it pertains to all three study arms and not just the 3rd treatment modality here. The test on blood and urine testing has been moved to the earlier section as suggested by the reviewer.
Sample size calculation Anticipating only nine (7%) drop outs across the study period seems optimistic! Further information/reference/s needed to support authors' assumption that "the non-inferiority limit of 14% ... would be likely to maintain cost effectiveness". The text has been altered to reflect the likely clinical relevance.
Safety reporting Probably unnecessary to list the various categories not being regarded as adverse events here. We felt it was helpful to describe the exclusions from safety reporting since this has enabled us to carry out this CTMP in this population. The safety reporting for the trial would be very arduous If we didn't have the exclusions. We thought this approach may be helpful for others setting up CTMP studies in IEPS settings.
Analysis plan
The three sub-cohorts should be compared demographically etc to assess the randomisation. This sub-section should also include plans for assessing the other study objectives including HCV reinfection rates, resistance profiles and drug interactions. Text has been added to include re-infection analysis. Analysis plans for blood and urine samples have not yet been finalised since we are waiting to see whether we have any people who do not achieve SVR12 despite having adherence patterns consistent with expectation of successful treatment.
More minor points The study compares three different ways of administering/dispensing DAAs, and not the actual treatment regimens (as per the article's title), which are the same across the three arms. While also referring more correctly to the different 'treatment dispensing regimens' in the text, to avoid any confusion I suggest referring to the three study arms as [treatment] 'modalities' instead of '[dispensing] regimens' throughout. We believe that the term regimen refers to the pattern of dispensing and not just the length of treatment (https://dictionary.cambridge.org/dictionary/english/regimen). Thus the 3 different groups have different regimens.
Suggest more common 'needle syringe programs' term instead of 'injecting equipment provision sites' for this international journal. 'Hepatitis' [C virus] does not need upper case; DAA 'treatment' and 'therapy' used interchangeablysuggest 'treatment' throughout; re: DAAs, suggest using 'medication' instead of 'drug' in a paper which also refers to illicit 'drug' use. Abbreviations not always preceded by the term in full (esp in Abstract), or full term used despite previously being abbreviated; some assumed abbreviations (e.g. NHS) should be in full. Text edited to reflect these suggestions.
Text waxes between present and future tense -should be consistent, and probably present tense since the study is currently in train. Text reviewed and tense corrected .
Some long-winded paragraphs and sentences (e.g. page 5, line 47 -51; page 6, para 1,2; page 8, lines:22-27), which could be shortened or fragmented, with information expressed more succinctly. Text reviewed and long winded passages improved. The study excludes those with severe liver disease who may not be suitable for the treatment options offered by the trial. This includes those with severe liver disease or with critical complications from liver disease. This is covered in the exclusion criteria (lines 177-179).
2.
How to treat patients who have received antiviral treatment in the past? Text added to Eligibility Criteria section 3.
There are many indicators of virology. Why do authors only consider SVR12? SVR12 is the recognised benchmark for long-term HCV viral clearance, this was considered appropriate as the trial is aiming to assess long-term viral response to HCV treatment with DAAs across alternate dispensing regimens. Further virologic analysis is planned for those participants who do not achieve SVR12, but adhered sufficiently to DAA treatment. 4.
Why not collect blood samples during follow-up to understand the change trend of patient's serum viral load? Follow-up in this study population is very challenging and we could not guarantee our ability to adequately collect these samples, further we do not want to subject participants to overly onerous follow-up procedures beyond what's minimally required to evidence the primary outcome.
5.
The subjects should be randomly grouped, and the method of random grouping is not given in the scheme. Text added (line 321->) 6.
Please explain how to improve the compliance of the subjects during the follow-up process. There is no specific intervention to improve compliance across all trial participants. There is one specific intervention designed to improve adherence to therapy, administered before treatment start, in the psychological intervention group. This is outlined in the paper (line 280 onwards). The intervention booklet can be provided as supplementary material if desired.
